Press release
X-Linked Retinitis Pigmentosa Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, MOA, ROA and Companies by DelveInsight
X-Linked Retinitis Pigmentosa Clinical Trials
In the X-Linked Retinitis Pigmentosa Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, X-Linked Retinitis Pigmentosa NDA approvals (if any), and product development activities comprising the technology, X-Linked Retinitis Pigmentosa collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
To explore more information on the latest breakthroughs in the X-Linked Retinitis Pigmentosa Pipeline treatment landscape of the report, click here @ X-Linked Retinitis Pigmentosa Pipeline Outlook- https://www.delveinsight.com/report-store/x-linked-retinitis-pigmentosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Key Takeaways from the X-Linked Retinitis Pigmentosa Pipeline Report
• DelveInsight's X-Linked Retinitis Pigmentosa Pipeline analysis depicts a robust space with 5+ active players working to develop 5+ pipeline treatment therapies.
• The leading companies working in the X-Linked Retinitis Pigmentosa market include Biogen, 4D Molecular therapeutics, Applied Genetics Technology Corporation, Janssen Research & Development LLC, MeiraGTx UK II Ltd, Syne Qua Non Limited, Bionical Emas, Frontera Therapeutics, DSM Nutritional Products Inc., and others.
• PromisingX-Linked Retinitis Pigmentosa Pipeline Therapies in the various stages of development include Genetic: AAV5-RPGR, AAV2/5-RPGR, FT-002, Docosahexaenoic Acid OR corn/Soy Oil placebo, and others.
• April 2024:- Janssen Pharmaceuticals- Phase 3 Study to Evaluate the Safety and Efficacy of AAV5-hRKp.RPGR for the Treatment of Japanese X-linked Retinitis Pigmentosa Associated With Pathogenic Variants in Retinitis Pigmentosa GTPase Regulator (RPGR). The purpose of the study is to assess the safety and tolerability of bilateral subretinal delivery of adeno-associated virus vector with a serotype 5 capsid human rhodopsin kinase promoter. retinitis pigmentosa guanosine triphosphatase regulator (AAV5-hRKp.RPGR).
• April 2024:- Beacon Therapeutics- A Randomized, Controlled, Masked, Multi-center Study Evaluating the Efficacy, Safety, and Tolerability of Two Doses of AGTC-501 Compared to an Untreated Control Group in Male Participants With X-linked Retinitis Pigmentosa. This study will evaluate and compare the safety, efficacy, and tolerability of 2 doses of a recombinant adeno-associated virus vector (AGTC-501) to an untreated control group in male participants with X-linked retinitis pigmentosa caused by RPGR mutations.
X-Linked Retinitis Pigmentosa Overview
X-linked Retinitis Pigmentosa is a rare, hereditary progressive genetic disorder associated with the gene mutation in chromosome X of an individual. This disorder is characterized by the progressive degeneration of photoreceptor cells in the retina and gradually leading to peripheral vision loss.
For further information, refer to the detailed X-Linked Retinitis Pigmentosa Unmet Needs, click here for X-Linked Retinitis Pigmentosa Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/x-linked-retinitis-pigmentosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
X-Linked Retinitis Pigmentosa Emerging Drugs Profile
• BIIB 112 (NSR-RPGR): Biogen
• 4D-125: 4 D Molecular Therapeutics
X-Linked Retinitis Pigmentosa Pipeline Therapeutics Assessment
There are approx. 5+ key companies which are developing the therapies for X-linked Retinitis Pigmentosa. The companies which have their X-linked Retinitis Pigmentosa drug candidates in the mid to advanced stage, Phase II/III include, Biogen and others.
Request a sample and discover the recent advances in X-Linked Retinitis Pigmentosa Ongoing Clinical Trial Analysis and Medications, Click here for more details @ X-Linked Retinitis Pigmentosa Segmentation- https://www.delveinsight.com/sample-request/x-linked-retinitis-pigmentosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
X-Linked Retinitis Pigmentosa Drugs and Companies
• Genetic: AAV5-RPGR: MeiraGTx UK II Ltd
• FT-002: Frontera Therapeutics
• Docosahexaenoic Acid OR Corn/Soy Oil Placebo: Retina Foundation of the Southwest/ DSM Nutritional Products Inc.
X-Linked Retinitis Pigmentosa Therapeutics Assessment
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Some of the Companies in the X-Linked Retinitis Pigmentosa Therapeutics Market include-
Biogen, 4D Molecular Therapeutics, Applied Genetics Technology Corporation, Janssen Research & Development LLC, MeiraGTx UK II Ltd, Syne Qua Non Limited, Bionical Emas, Frontera Therapeutics, DSM Nutritional Products Inc., and others.
Dive deep into rich insights for drugs for the X-Linked Retinitis Pigmentosa Pipeline, Click here @ X-Linked Retinitis Pigmentosa Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/x-linked-retinitis-pigmentosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the X-Linked Retinitis Pigmentosa Pipeline Report
• Coverage- Global
• Companies- Biogen, 4D Molecular therapeutics, Applied Genetics Technology Corporation, Janssen Research & Development LLC, MeiraGTx UK II Ltd, Syne Qua Non Limited, Bionical Emas, Frontera Therapeutics, DSM Nutritional Products Inc., and others.
• Therapies- Genetic: AAV5-RPGR, AAV2/5-RPGR, FT-002, Docosahexaenoic Acid OR corn/Soy Oil placebo, and others.
• Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on X-Linked Retinitis Pigmentosa Merger and acquisitions, Licensing Activities- https://www.delveinsight.com/sample-request/x-linked-retinitis-pigmentosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Content
1. Introduction
2. Executive Summary
3. X-linked Retinitis Pigmentosa: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. X-linked Retinitis Pigmentosa - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. X-linked Retinitis Pigmentosa Collaboration Deals
9. Late Stage Products (Phase II/III)
10. BIIB 112 (NSR-RPGR): Biogen
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase I/II)
13. 4D-125: 4 D Molecular Therapeutics
14. Drug profiles in the detailed report…..
15. Pre-clinical and Discovery Stage Products
16. Drug profiles in the detailed report…..
17. Inactive Products
18. X-linked Retinitis Pigmentosa Key Companies
19. X-linked Retinitis Pigmentosa Key Products
20. X-linked Retinitis Pigmentosa- Unmet Needs
21. X-linked Retinitis Pigmentosa- Market Drivers and Barriers
22. X-linked Retinitis Pigmentosa- Future Perspectives and Conclusion
23. X-linked Retinitis Pigmentosa Analyst Views
24. X-linked Retinitis Pigmentosa Key Companies
25. Appendix
Trending Report:
• Vascular Access Devices Market: https://www.delveinsight.com/report-store/vascular-access-device-market
• Ashermans Syndrome Market: https://www.delveinsight.com/sample-request/ashermans-syndrome-market
• Central Venous Catheters Market: https://www.delveinsight.com/report-store/central-venous-catheters-market
• Absssi Market Size: https://www.delveinsight.com/report-store/acute-bacterial-skin-and-skin-structure-infection-absssi-market-insights-epidemiology-and-market-forecast
• Gaucher Disease Market: https://www.delveinsight.com/report-store/gauchers-disease-market
• Aortic Aneurysm Stent Grafts Market: https://www.delveinsight.com/report-store/aortic-aneurysm-stent-grafts-market
• Neurotrophic Keratitis Market: https://www.delveinsight.com/report-store/neurotrophic-keratitis-market
• Xerostomia Market: https://www.delveinsight.com/report-store/xerostomia-market
• Bunion Market: https://www.delveinsight.com/report-store/bunion-market
• Chronic Bronchitis Market: https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-market
• Concussions Market Size: https://www.delveinsight.com/report-store/concussions-market
• Hepatitis D Market: https://www.delveinsight.com/report-store/hepatitis-d-market
• Neuroblastoma Market: https://www.delveinsight.com/report-store/neuroblastoma-market
• Pressure Ulcers Market: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Alpha-mannosidosis Market: https://www.delveinsight.com/report-store/alpha-mannosidosis-market
• Biliary Atresia Market: https://www.delveinsight.com/report-store/biliary-atresia-market
• Chronic Plaque Psoriasis Market: https://www.delveinsight.com/report-store/chronic-plaque-psoriasis-market
• Chronic Rhinosinusitis Market: https://www.delveinsight.com/report-store/chronic-rhinosinusitis-with-nasal-polyps-market
• Energy Based Aesthetic Devices Market: https://www.delveinsight.com/report-store/energy-based-aesthetic-devices-market
• Epithelioid Sarcoma Market: https://www.delveinsight.com/report-store/epithelioid-sarcoma-market
• Pharma Licensing Services: https://www.delveinsight.com/consulting/licensing-services
• Acquired Hemophilia A Pipeline: https://www.delveinsight.com/report-store/acquired-hemophilia-a-pipeline-insight
• Acute Coronary Syndrome Market: https://www.delveinsight.com/report-store/acute-coronary-syndrome-market
• Anal Cancer Market: https://www.delveinsight.com/report-store/anal-cancer-market
• Cerebral Vein Thrombosis Market: https://www.delveinsight.com/report-store/cerebral-vein-thrombosis-market
• Chronic Rhinosinustis Market: https://www.delveinsight.com/report-store/chronic-rhinosinusitis-with-nasal-polyps-market
• Community-acquired Bacterial Pneumonia Market: https://www.delveinsight.com/report-store/community-acquired-bacterial-pneumonia-cabp-market
• Familial Amyloid Polyneuropathy Market: https://www.delveinsight.com/report-store/familial-amyloid-polyneuropathy-transthyretin-amyloidosis-corino-de-andrades-disease-market
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/business-development-services
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release X-Linked Retinitis Pigmentosa Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, MOA, ROA and Companies by DelveInsight here
News-ID: 3850039 • Views: …
More Releases from DelveInsight Business Research
Cushing's Syndrome Pipeline 2025: Therapies, MOA Insights, and Key Clinical Tria …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Cushing's Syndrome pipeline constitutes 4+ key companies continuously working towards developing 4+ Cushing's Syndrome treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Cushing's Syndrome Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Cushing's Syndrome Market.
The Cushing's…
Chronic Traumatic Encephalopathy Pipeline 2025: MOA, ROA, FDA-Approved Drugs, an …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Chronic Traumatic Encephalopathy pipeline constitutes 4+ key companies continuously working towards developing 4+ Chronic Traumatic Encephalopathy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Chronic Traumatic Encephalopathy Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Traumatic…
Meibomian Gland Dysfunction Pipeline 2025: In-depth Clinical Trials Analysis and …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Meibomian Gland Dysfunction pipeline constitutes 4+ key companies continuously working towards developing 4+ Meibomian Gland Dysfunction treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Meibomian Gland Dysfunction Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Meibomian Gland…
Lupus Nephritis Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Lupus Nephritis pipeline constitutes 35+ key companies continuously working towards developing 40+ Lupus Nephritis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Lupus Nephritis Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Lupus Nephritis Market.
The Lupus…
More Releases for Retinitis
Retinitis Pigmentosa Therapeutics Analysis, Clinical Trials and Other Developmen …
Retinitis pigmentosa therapeutics currently exhibits a proliferating pipeline with 25+ therapeutic candidates.
Retinitis pigmentosa (RP) is a group of hereditary disorders that lead to the breakdown and loss of cells in the retina. Mutation in genes encoding the proteins required by retinal cells for their proper functioning, results in occurrence of RP. The disease results in partial vision loss during the earlier stage of the disease, which may lead to complete…
Retinitis Pigmentosa (RP) Market Focusing on intrinsic limitations 2025
Global Retinitis Pigmentosa (RP) Market: Snapshot
Retinitis pigmentosa, in which patients usually lose night vision in teenage years, side vision in middle age, and central vision in later life because of steady loss of cone photoreceptor cells and rod. Measures of retinal function, such as the electroretinogram, indicate that photoreceptor function is reduced usually several years before visual-field scotomas, symptomic night blindness, or reduced visual acuity arise.
Request Sample Copy of…
Retinitis Pigmentosa (Retinitis) Industry Market Expected To Grow At High Cagr D …
Overview
Retinitis Pigmentosa (RP) refers to a group of diseases which cause a slow but progressive vision loss. Retinitis pigmentosa is caused by a genetic defect. Symptoms include night blindness and loss of peripheral vision. The predisposing factors include autosomal dominant inheritance, autosomal recessive inheritance and x-linked inheritance.
Click here for sample report @ http://www.wiseguyreports.com/sample-request/2740087-retinitis-pigmentosa-retinitis-pipeline-review-h2-2017
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2017, provides comprehensive…
Market Research Focuses on Retinitis Pigmentosa (Retinitis) Market Pipeline Revi …
"The Report Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2017, provides an overview of the Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline landscape.
Retinitis Pigmentosa (RP) refers to a group of diseases which cause a slow but progressive vision…
Global Cytomegalovirus Retinitis Market Size, Share | MarketResearchReports.biz
Latest industry research report on: Global Cytomegalovirus Retinitis Market : Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts
Cytomegalovirus (CMV) Retinitis is caused by cytomegalovirus infection, which is a herpes-type virus that affects the retina of the human eye among patients having a weak immune system that could be due to conditions such as AIDS, leukemia and/or pregnancy. Symptomatic conditions include floaters, flashes, and blind spots besides…
Retinitis Pigmentosa (Retinitis) Pipeline Insight and Therapeutic Assessment Rev …
Market Research Hub (MRH) has recently broadcasted a new study to its broad research portfolio, which is titled as “Retinitis Pigmentosa (Retinitis)-Pipeline Insights, 2017, report provides comprehensive insights of the ongoing therapeutic research and development across Retinitis Pigmentosa (Retinitis). The report provides a complete understanding of the pipeline activities covering all clinical, pre-clinical and discovery stage products. A comparative pipeline therapeutics assessment of Retinitis Pigmentosa (Retinitis) by development stage, therapy…
